Mechanochemical Endovenous Ablation of Small Saphenous Vein Insufficiency Using the ClariVein® Device: One-year Results of a Prospective Series

ObjectiveThis study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous ablation (MOCA™) of small saphenous vein (SSV) insufficiency.DesignProspective cohort study.Materials and methodsFifty consecutive patients were treated for primary SSV insufficiency with MOCA™ using the ClariVein® device and polidocanol. Initial technical success, complications, patient satisfaction and visual analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1 year.ResultsInitial technical success of MOCA™ was 100%. At the 6-week assessment, all treated veins were occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% confidence interval, 0.87–1). Venous clinical severity score (VCSS) decreased significantly from 3.0 (interquartile range (IQR) 2–5) before treatment to 1.0 (IQR 1–3, P < 0.001) at 6 weeks and to 1.0 (IQR 1–2, P < 0.001) at 1 year. Median procedural VAS score for pain was 2 (IQR 2–4). No major complications were observed, especially no nerve injury.ConclusionsMOCA™ is a safe, feasible and efficacious technique for treatment of SSV insufficiency. One-year follow-up shows a 94% anatomic success rate and no major complications.